Vallesiachotamine and isovallesiachotamine are pharmacologically active monoterpene indole alkaloids produced by Catharanthus roseus. However, the biosynthetic pathway for these two alkaloids has not been characterized. The results of our experiments demonstrated that catharanthine induced the biosynthesis of vallesiachotamine and isovallesiachotamine in C. roseus cambial meristematic cells (CMCs) in a time-and dosage-dependent manner. The highest yields of vallesiachotamine and isovallesiachotamine (i.e., 1.49 mg l −1 and 1.08 mg l −1 , respectively) were observed in CMCs treated with 10 mg catharanthine l −1 for 12 h. The cells growth was inhibited by 20 mg catharanthine l −1 (i.e., 16.3% decrease in dry-cell weight). A quantitative reverse transcription polymerase chain reaction analysis revealed that catharanthine regulated the biosynthesis of vallesiachotamine and isovallesiachotamine by upregulating the expression of specific genes, including STR (strictosidine synthase), SGD (strictosidine β-D-glucosidase) and ORCA3 (transcription factor octadecanoid-responsive Catharanthus AP2/ERF-domain 3). Finally, considering the up-regulated expression of STR and SGD was consistent with the accumulation of vallesiachotamine and isovallesiachotamine, a potential vallesiachotamine and isovallesiachotamine biosynthetic pathway was proposed.
More than 130 Catharanthus roseus terpene indole alkaloids (TIAs) have been isolated and identified [1] . Some TIAs, such as vinblastine, vincristine, ajmalicine, and vallesiachotamine, exhibit strong pharmacological activities [2] [3] [4] . Vallesiachotamine isolated from C. roseus is considerably cytotoxic to human melanoma cell line SK-MEL-37, making it an attractive potential chemotherapeutic drug [5] . Although C. roseus has been extensively studied, its alkaloid biosynthetic pathway has not been fully characterized. Additionally, there is currently no published article regarding the vallesiachotamine and isovallesiachotamine biosynthetic pathway.
The production of secondary metabolites in dedifferentiated C. roseus cells is unstable and low yielding [6] . The absence of key biosynthetic genes in cultured dedifferentiated plant cells is the primary reason for the low yields of secondary metabolites [7] . However, the marker genes and transcriptional programs of innately undifferentiated cambial meristematic cells (CMCs) are consistent with stem cell identity, resulting in the production of abundant secondary metabolites [8] . We previously isolated and cultured C. roseus CMCs [9] , and found that catharanthine, vindoline, and ajmalicine could be stably produced in these cells after 2 years of culturing.
One of the most effective methods to enhance the production of important secondary metabolites in plant cells involves the use of elicitors [10, 11] . The production of TIAs in C. roseus cultured cells could be induced by abiotic and biotic elicitors [12] . This paper reports the investigations of catharanthine metabolism in cultured C. roseus CMCs. The results revealed that catharanthine could induce the biosynthesis of vallesiachotamine and isovallesiachotamine in a time-and dosage-dependent manner.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) results confirmed that catharanthine up-regulates the expression of STR (strictosidine synthase), SGD (strictosidine β-Dglucosidase), and ORCA3 (transcription factor octadecanoidresponsive Catharanthus AP2/ERF-domain 3). Based on our results, we propose a plausible biosynthetic pathway for vallesiachotamine and isovallesiachotamine in C. roseus.
Vallesiachotamine and isovallesiachotamine were detected only in the extracts from cells treated with catharanthine. Additionally, they were produced in CMCs in a time-dependent manner ( Figure 1) , with the greatest production occurring at 12 h (vallesiachotamine: 1.49 mg l −1 ; isovallesiachotamine: 1.08 mg l −1 ). Based on the up-regulated STR and SGD expression levels which were consistent with the accumulation of vallesiachotamine and isovallesiachotamine, a potential biosynthetic pathway for these monoterpene indole alkaloids was proposed ( Figure 5 ).
Catharanthine, vindoline and ajmalicine were stably produced in CMCs, while vallesiachotamine and isovallesiachotamine were not detected. We unexpectedly observed that catharanthine elicits the production of vallesiachotamine and isovallesiachotamine in suspension-cultured CMCs. Elicitors, such as β-cyclodextrin and methyl jasmonate, are capable of promoting the biosynthesis of phytoalexins by inducing a defense response, may help to increase the production of secondary metabolites in plant cells [13] . Most plant secondary metabolites are cytotoxic at high concentrations [14] . Thus, we hypothesized that a high catharanthine concentration (e.g., 10 mg l −1 ) induces a defense response in suspension-cultured CMCs, ultimately leading to the accumulation of vallesiachotamine and isovallesiachotamine.
Although the C. roseus TIA biosynthetic pathway has been extensively studied, the vallesiachotamine and isovallesiachotamine biosynthetic pathway remains uncharacterized. A previous study by Shen [15] concluded that strictosidine could be biotransformed to vallesiachotamine and isovallesiachotamine in bacteria. Strictosidine is a key intermediate in the biosynthesis of more than 130 C. roseus TIAs. Strictosidine synthase（STR） is responsible for the stereospecific condensation of tryptamine and secologanin to form strictosidine. The strictosidine is then transformed to an aglycone by specific SGDs before ultimately forming various monoterpenoid indole alkaloids [16] . Expression of the ORCA3 gene for a transcription factor is induced by jasmonates that regulate the expression of STR and SGD in cell suspension cultures [17] which is also responsible for the production of vallesiachotamine and isovallesiachotamine. Results at the present experiment showed that catharanthine up-regulates the STR, SGD and ORCA3 expression levels which influences the production of vallesiachotamine and isovallesiachotamine in C. roseus CMCs. Based on qRT-PCR results, the vallesiachotamine and isovallesiachotamine biosynthetic pathway was proposed in C. roseus ( Figure 5 ).
Vallesiachotamine and isovallesiachotamine biosynthetic pathway
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Experimental
Plant materials: The C. roseus CMCs were sub-cultured every 2 weeks as previously described by our group [9] . The cells were cultivated in liquid Murashige and Skoog medium supplemented with α-naphthalene acetic acid l −1 (NAA, 1.0 mg) and 30 g sucrose l −1 . The pH of the medium was adjusted to 5.8 before autoclaving. The CMCs (50 g l −1 fresh weight) were added to 250-mL Erlenmeyer flasks containing 100 mL liquid medium. The suspension-cultured cells were grown at 25°C on a rotary shaker (110 rpm) for 12 days under constant light.
Treatment with catharanthine:
The solution of catharanthine was prepared in DMSO. Then, two sets of experiments were performed. In the first set, 12-day-old cultures were treated with catharanthine in a final concentration of 10 mg. l -1. The cells were harvested at different periods (2, 6, 12, 24 , and 48 h, respectively). In the second set, 12-day-old cultures were treated with catharanthine in five final concentrations (1, 5, 10, 15, 20 mg.l -1 ). The cultures were harvested at 12 h. Controls treated with the same volume of DMSO. All values are mean of 3 cultures, replicated 3 times.
Isolation and elucidation of products:
After the incubation period, the cells and medium were separated by filtration. The cells were dried at 55°C. When the total elimination of water was achieved, the dried cells were weighed, and then sonicated in methanol three times. After concentrating the combined extract solutions in a vacuum, the residue was dissolved in 2.5% sulfuric acid (v/v) and washed twice with ethyl acetate. The pH value of the aqueous solution was adjusted to 10, after which the solution was partitioned three times using ethyl acetate. The ethyl acetate layer was concentrated in a vacuum, and the resulting residue was resuspended in methanol. The medium samples were partitioned using ethyl acetate after the pH was adjusted to 10. The ethyl acetate extracts were combined and then dried. The residue was dissolved in methanol. The controls were similarly prepared. The alkaloid fractions of the cell extracts were isolated with a basic alumina column and a semi-preparative high-performance liquid chromatography (HPLC). The products were determined by HPLC. An Agilent 1260 series system and a Phenomenex Gemini C18 column (250 × 4.6 mm, 5 μm particles) were used. The mobile phase consisted of methanol/acetonitrile/10 mM ammonium acetate (15:40:45, v/v/v) at a flow rate of 1.0 mL min −1 . The detection wavelength was 280 nm and the injection volume was 10 μL. The yields of the products were calculated by using the peak areas and calibration curves obtained with standards of known concentration. Vallesiachotamine, isovallesiachotamine and catharanthine were purchased from Aladdin Reagents Co. Product structures were determined based on physico-chemical properties and spectral analyses ( 1 H and 13 C nuclear magnetic resonance and electrospray mass spectrometry).
RNA extraction and qRT-PCR: Catharanthine l −1 (10 mg) was added to 12-day-old cultures, while the control group was treated with an equal volume of DMSO only. All of them were incubated for additional 12 h, then cultured cells were frozen in liquid nitrogen and ground into powder using a mortar and pestle. Total RNA was subsequently extracted from the ground material as described above [9] . A NanoDrop ND-1000 spectrophotometer (Thermo Scientific) was used to quantify the concentration of RNA. Residual genomic DNA was eliminated from 1 μg total RNA, after which cDNA was synthesized using the PrimeScript™ RT Reagent Kit with gDNA Eraser (Takara, Japan). The gene-specific primer sequences for RPS9 (the housekeeping gene), STR, ORCA3 and SGD are provided in Supplementary Table 1 [9] . The qRT-PCR was conducted using the SYBR ® Premix Ex Taq™ (Tli RNaseH Plus) master mix (Kyoto, Japan) and the 48-well MJ Mini thermal cycler (Bio-Rad, USA). The qRT-PCR program was as follows: 95°C for 30 s; 40 cycles of 95°C for 5 s and 60°C for 20 s. After the 40 cycles, a melting curve analysis (60-95°C) was completed to verify the specificity of the amplifications. The qRT-PCR data were used to analyze gene expression stability with Bio-Rad CFX Manager software.
